<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8525C80A-080A-4EC7-90F8-ED6BB8560C64"><gtr:id>8525C80A-080A-4EC7-90F8-ED6BB8560C64</gtr:id><gtr:name>Animal Health and Veterinary Laboratories Agency (AHVLA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9ED220E4-E93E-4738-ACD1-D5B2B708EBBB"><gtr:id>9ED220E4-E93E-4738-ACD1-D5B2B708EBBB</gtr:id><gtr:name>Aeras</gtr:name><gtr:address><gtr:line1>1405 Research Blvd</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/150CE820-6372-414E-9F7F-524E27034E23"><gtr:id>150CE820-6372-414E-9F7F-524E27034E23</gtr:id><gtr:name>University of Colorado at Boulder</gtr:name><gtr:address><gtr:line1>Boulder</gtr:line1><gtr:line4>Colorado</gtr:line4><gtr:line5>80309-0425</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB2319AB-8EEB-445A-8BB6-43D47D979CA9"><gtr:id>BB2319AB-8EEB-445A-8BB6-43D47D979CA9</gtr:id><gtr:name>Biomedical Primate Research Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7355F8C7-3098-42E6-B5E2-58A80A8ECF36"><gtr:id>7355F8C7-3098-42E6-B5E2-58A80A8ECF36</gtr:id><gtr:name>Animal and Plant Health Agency</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>Livestock Viral Diseases</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8525C80A-080A-4EC7-90F8-ED6BB8560C64"><gtr:id>8525C80A-080A-4EC7-90F8-ED6BB8560C64</gtr:id><gtr:name>Animal Health and Veterinary Laboratories Agency (AHVLA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9ED220E4-E93E-4738-ACD1-D5B2B708EBBB"><gtr:id>9ED220E4-E93E-4738-ACD1-D5B2B708EBBB</gtr:id><gtr:name>Aeras</gtr:name><gtr:address><gtr:line1>1405 Research Blvd</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/150CE820-6372-414E-9F7F-524E27034E23"><gtr:id>150CE820-6372-414E-9F7F-524E27034E23</gtr:id><gtr:name>University of Colorado at Boulder</gtr:name><gtr:address><gtr:line1>Boulder</gtr:line1><gtr:line4>Colorado</gtr:line4><gtr:line5>80309-0425</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19A2A787-2FDB-4397-9885-403B7C582232"><gtr:id>19A2A787-2FDB-4397-9885-403B7C582232</gtr:id><gtr:name>Leiden University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB2319AB-8EEB-445A-8BB6-43D47D979CA9"><gtr:id>BB2319AB-8EEB-445A-8BB6-43D47D979CA9</gtr:id><gtr:name>Biomedical Primate Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7355F8C7-3098-42E6-B5E2-58A80A8ECF36"><gtr:id>7355F8C7-3098-42E6-B5E2-58A80A8ECF36</gtr:id><gtr:name>Animal and Plant Health Agency</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ED099116-52CF-41E1-9F99-2ED0F3056923"><gtr:id>ED099116-52CF-41E1-9F99-2ED0F3056923</gtr:id><gtr:firstName>Elma</gtr:firstName><gtr:otherNames>Zaven</gtr:otherNames><gtr:surname>Tchilian</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2735F8CB-B1F6-4566-A8EA-7434499EA3D0"><gtr:id>2735F8CB-B1F6-4566-A8EA-7434499EA3D0</gtr:id><gtr:firstName>Ajit</gtr:firstName><gtr:surname>Lalvani</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B26F84B8-BD99-458F-87FD-67E85D1959E8"><gtr:id>B26F84B8-BD99-458F-87FD-67E85D1959E8</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Beverley</gtr:surname><gtr:orcidId>0000-0003-0481-2180</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100085"><gtr:id>6DB8A598-A5E5-4119-92D3-48A2D900EF60</gtr:id><gtr:title>Simultaneous parenteral and pulmonary immunisation against tuberculosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100085</gtr:grantReference><gtr:abstractText>Two million individuals die each year from tuberculosis infection, which is an increasing problem because HIV/AIDS makes individuals highly susceptible and because antibiotic resistant strains of Mycobacterium tuberculosis are appearing. The present tuberculosis vaccine, BCG, is only partially effective, so development of a better vaccine is an urgent health care priority. Up to now, most new tuberculosis vaccines have been designed to be given after BCG, in order to boost the weak immunity provided by BCG. This is called prime boost immunisation. However, it is becoming clear that prime boost immunisation may not be sufficiently effective to control tuberculosis.
In this project we will establish an alternative novel immunisation strategy called Simultaneous Immunisation (SIM). We have already shown that giving one tuberculosis vaccine by injection and simultaneously spraying another into the lungs is highly effective in mice. The lung vaccine establishes local immunity, which combats tuberculosis infection immediately after infection, and the injected vaccine has a slower effect, but the two work very effectively together. We now want to test several different SIM regimes in mice to find the most effective one and test its safety. We will also study how different white cells combine to protect the lungs against tuberculosis, in order to make even more effective vaccines in the future. At the same time we will study humans infected with tuberculosis to develop better tests to assess immunity to tuberculosis. This will help in testing new immunisation procedures, including SIM, in man. A better tuberculosis vaccine will have major health benefits for humans and can also be used to control bovine tuberculosis, which is currently widespread in the UK and causes considerable economic losses.</gtr:abstractText><gtr:technicalSummary>Tuberculosis vaccinology is dominated by the prime boost paradigm. In this project we will establish the novel concept of simultaneous immunisation (SIM) against Mycobacterium tuberculosis (Mtb). We will determine the roles of different lung and peripheral lymphocyte populations in protective immunity induced by SIM in mice, and develop assays for protective pulmonary immunity in man.
In mice intranasal immunisation with the subunit Mtb vaccine, Ad85A, generates pulmonary immunity. Importantly, Mtb growth is inhibited immediately after challenge. In contrast, parenteral BCG or subunit vaccines only inhibit Mtb growth late after challenge. The additive effect of parenteral/pulmonary immunisation does not depend on prime/boosting but on targeting early and late Mtb growth. Therefore SIM should be possible. We have demonstrated in practice that it is highly effective.
We will determine the efficacy, duration and mechanism of protection of SIM. SIM safety will be tested by assessing immune responses and pathology after coincident infection with influenza virus or induction of allergic lung responses. 
Expression of the chemokine/receptor pair CXCL16/CXCR6 in the lungs after pulmonary immunisation is a correlate of protective pulmonary immunity. CXCR6+ cells are recoverable in bronchoalveolar lavage (BAL) unlike antigen specific cells induced by parenteral vaccines. However, three cell populations take part in pulmonary protection against Mtb, BAL cells, interstitial lung cells and extrapulmonary lymphocytes, but their roles in early and late inhibition of Mtb growth after challenge are ill-defined, as is the function of CXCL16/CXCR6 in intrapulmonary localization of cells. We shall use in vivo antibody depletion/blocking or transfer of purified cells to determine the function of different cells in early or late growth inhibition and the migration inhibitor, fingolimod, to dissect the contribution of intrapulmonary and extrapulmonary cells. CXCL16/CXCR6 deficient mice will illuminate the role of these molecules. 
We will develop assays for human pulmonary immunity by quantifying immune mediators in nasal and bronchial fluid or supernatants of cultured nasal epithelial cells, BAL or peripheral blood lymphocytes from Mtb un-exposed, Mtb exposed, latently infected subjects or Tb patients. 
This project will establish SIM as a highly effecive and safe method, which would require only a single clinic visit. We will determine the roles of different Tb-immune populations in protective lung immunity and the roles of CXCL16/CXCR6 in localization of cells within the lung. We will identify candidate assays for future assessment of immunity after pulmonary immunisation in man.</gtr:technicalSummary><gtr:fund><gtr:end>2014-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1027875</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Department of Infectious Diseases</gtr:department><gtr:description>TB antigens for vaccine testing and diagnostics</gtr:description><gtr:id>8AC3212D-8DF0-44C3-A504-B88B15498E33</gtr:id><gtr:impact>Two joint publications.</gtr:impact><gtr:outcomeId>ep7QobLRDoo-1</gtr:outcomeId><gtr:partnerContribution>Partners provide TB antigens for vaccine testing and diagnostics.</gtr:partnerContribution><gtr:piContribution>We provide the mouse model and the SIM strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>To test the common respiratory mucosal concept by examining nasal and lung immune responses to TB antigen</gtr:description><gtr:id>98731EBE-BACD-4992-803B-450152D7A2F4</gtr:id><gtr:impact>Colleagues at Imperial continue to work on human immune responses to MTb. Two joint publications.</gtr:impact><gtr:outcomeId>EsnGV6LguHP-1</gtr:outcomeId><gtr:partnerContribution>Partners will test human lung and nasal immune responses to BCG.</gtr:partnerContribution><gtr:piContribution>We provide the mouse model and SIM strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aeras</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Aeras Global TB Vaccine Foundation</gtr:department><gtr:description>To test novel immunisation strategy SIM in mouse model</gtr:description><gtr:id>7F51844B-F972-4704-9A9C-47DCBA2639BC</gtr:id><gtr:impact>Experiment completed, but not yet published.</gtr:impact><gtr:outcomeId>bv4r3s6P6cn-1</gtr:outcomeId><gtr:partnerContribution>Partners - they will carry out simultaneous immunisation (SIM) in mice administering BCG or recombinant antigen 85A by pulmonary and parenteral routes.</gtr:partnerContribution><gtr:piContribution>Our contribution - discovery of the new immunisation strategy SIM.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Animal Health And Veterinary Laboratories Agency (AHVLA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>To test novel immunisation strategy SIM in cows</gtr:description><gtr:id>E2B8A9CD-844D-462C-ABF0-ACC90A623B98</gtr:id><gtr:impact>Testing of SIM in cows, showed increased protection compared to parenteral BCG alone.
Joint publication.</gtr:impact><gtr:outcomeId>cW9WVL2cvaD-1</gtr:outcomeId><gtr:partnerContribution>Partners - they will carry out simultaneous immunisation (SIM) in cows administering BCG by pulmonary and parenteral routes.</gtr:partnerContribution><gtr:piContribution>Our contribution - discovery of the new immunisation strategy SIM.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Animal and Plant Health Agency</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>To test novel immunisation strategy SIM in cows</gtr:description><gtr:id>7A45E58C-F8B4-47DF-AB34-28A99E45DA11</gtr:id><gtr:impact>Testing of SIM in cows, showed increased protection compared to parenteral BCG alone.
Joint publication.</gtr:impact><gtr:outcomeId>cW9WVL2cvaD-2</gtr:outcomeId><gtr:partnerContribution>Partners - they will carry out simultaneous immunisation (SIM) in cows administering BCG by pulmonary and parenteral routes.</gtr:partnerContribution><gtr:piContribution>Our contribution - discovery of the new immunisation strategy SIM.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Colorado</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>To test novel immunisation strategy SIM in guinea pigs</gtr:description><gtr:id>DD82D11C-DF53-4297-8D5D-7E5294708C4C</gtr:id><gtr:impact>Testing of SIM in guinea pigs did not show increased protection over parenteral BCG alone.
Not yet published</gtr:impact><gtr:outcomeId>aUCz881YHVp-1</gtr:outcomeId><gtr:partnerContribution>Partners - they will carry out simultaneous immunisation (SIM) in guinea pigs administering BCG or recombinant antigen 85A by pulmonary and parenteral routes.</gtr:partnerContribution><gtr:piContribution>Our contribution - discovery of the new immunisation strategy SIM.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biomedical Primate Research Centre</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>To test novel immunisation strategy SIM in non-human primates</gtr:description><gtr:id>4A8B8A2E-2D7E-4FFE-9B7F-EDE24875AFF0</gtr:id><gtr:impact>Testing SIM in NHP showed that pulmonary administration of BCG is highly effective.
Manuscript in press (Tuberculosis): Variable BCG efficacy in rhesus populations: pulmonary BCG provides
protection where standard intra-dermal vaccination fails. Frank Verreck, Elma Z. Tchilian, Richard A.W. Vervenne, Claudia C. Sombroek,
Ivanela Kondova, Okke A. Eissen, Vinod Sommandas, Nicole M. van der Werff, Ernst Verschoor, Gerco Braskamp, Jaco Bakker, Jan A.M. Langermans, Peter J. Heidt, Tom H.M. Ottenhoff, Klaas W. van Kralingen, Alan W. Thomas, Peter
C.L. Beverley, Clemens H.M. Kocken</gtr:impact><gtr:outcomeId>b9N9n8RNyDM-1</gtr:outcomeId><gtr:partnerContribution>Partners - they will carry out simultaneous immunisation (SIM) in non-human primates administering BCG by pulmonary and parenteral routes.</gtr:partnerContribution><gtr:piContribution>Our contribution - discovery of the new immunisation strategy SIM.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max von Pettenkofer-Institute of Hygiene and Medical Microbiology</gtr:department><gtr:description>To explore the use of MCMV as a vaccine vector for TB</gtr:description><gtr:id>FFFBD328-1808-45BB-91E6-1D991D2377BA</gtr:id><gtr:impact>One joint publication.</gtr:impact><gtr:outcomeId>o8oahj6F8Xf-1</gtr:outcomeId><gtr:partnerContribution>Partners provide the viral constructs and provide help and advice on the virology.</gtr:partnerContribution><gtr:piContribution>We perform all of the in vivo work to test the efficacy of the MCMV constructs as TB vaccine vectors.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>work experience  for school children</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C301896-9620-4D31-9E8D-0B50D5FAE2F1</gtr:id><gtr:impact>provided work experience for 5 school children

The pupils performed very well in their A level exams and went on to further education.</gtr:impact><gtr:outcomeId>BPf8v9y9Tta</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The use of CXCR6 and CXC16 for diagnosis of the effectiveness of pulmonary immunisation or treatment of pulmonary infection.</gtr:description><gtr:grantRef>G1100085</gtr:grantRef><gtr:id>C47CD8A3-6248-49F4-98AB-22D1337B1AED</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>BWNJNcYHnjF</gtr:outcomeId><gtr:patentId>WO2012025759</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CXCR6</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An immunisation strategy, comprising simultaneous parenteral and lung administration of an antigen, against Mycobacterium Tuberculosis or Mycobacterium bovis.</gtr:description><gtr:grantRef>G1100085</gtr:grantRef><gtr:id>C15AE721-C77A-45ED-B646-047BD4632C09</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>dyDwkfo8T8t</gtr:outcomeId><gtr:patentId>WO2012052748</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>SIM</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>DEFRA policy advice on bovine TB</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC85A337-C089-4C3E-9639-4EE1E7E4BCED</gtr:id><gtr:outcomeId>TN11ukvxzq8</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>performed microarray analysis of lungs lymphocytes from MCMV infected mice</gtr:description><gtr:id>65AC3ACF-2790-4D65-AE69-C6B25B18A0DB</gtr:id><gtr:impact>Information of genes expression in the lungs of MCMV infected mice, which will have an impact on the design of CMV vaccine vectors and mechanisms of vaccine induced protection</gtr:impact><gtr:outcomeId>QArfLgXYNjY</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>microarray analysis</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>novel vaccine vector for tuberculosis</gtr:description><gtr:id>C1DA28CD-500E-40CC-BF2C-19AB61E91CCE</gtr:id><gtr:impact>novel vaccine vector for TB which offers persistence and long term protection.
Microrarray analysis after MCMV infection.</gtr:impact><gtr:outcomeId>DEcTgXAW4pj</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MCMV85A</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4D4FD49D-2B8C-4DEB-96C7-A8B84EA17671</gtr:id><gtr:title>Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2360a09cf36255b1c70e468e72ee2e71"><gtr:id>2360a09cf36255b1c70e468e72ee2e71</gtr:id><gtr:otherNames>Beverley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_13760_20_23262169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC1E652A-4534-4317-BA89-E930CAFA8BD0</gtr:id><gtr:title>Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine models.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea054cdcc4a6358feae93e08898253e2"><gtr:id>ea054cdcc4a6358feae93e08898253e2</gtr:id><gtr:otherNames>O'Sullivan DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_13760_10_17980937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D1A4675-D7AC-4EA3-9216-8680FB4BDE82</gtr:id><gtr:title>Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/424feadcace2178974491f6216119b08"><gtr:id>424feadcace2178974491f6216119b08</gtr:id><gtr:otherNames>Verreck FAW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>59148d6f171ab7.00734546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A15C3B2E-9961-47D6-9208-17050C6FF3F8</gtr:id><gtr:title>Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d708c6a947ee56beed79fb1b3a767d4"><gtr:id>4d708c6a947ee56beed79fb1b3a767d4</gtr:id><gtr:otherNames>Egeler RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>5a32465dcb06a5.85938505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>398B8FAA-C70F-4BDB-8F22-94CDA27584B2</gtr:id><gtr:title>Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec01007f9b88dd2817ad8edd660d0a46"><gtr:id>ec01007f9b88dd2817ad8edd660d0a46</gtr:id><gtr:otherNames>Ronan EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13760_20_20011050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17AB7A3B-DABC-4767-8C90-7114C3F9B0F1</gtr:id><gtr:title>A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f291f773af9424c3405959719846d950"><gtr:id>f291f773af9424c3405959719846d950</gtr:id><gtr:otherNames>Beverley PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_540e179e179e2ebf9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F651EF61-8DBF-4CF7-93A9-273A97DF279F</gtr:id><gtr:title>ESX1-dependent fractalkine mediates chemotaxis and Mycobacterium tuberculosis infection in humans.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95ac9a9f7f24361dbc0255b492291a3a"><gtr:id>95ac9a9f7f24361dbc0255b492291a3a</gtr:id><gtr:otherNames>Hingley-Wilson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>564b46a5d5b923.46403723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09C159C9-08C2-401E-976F-03F277DCD47F</gtr:id><gtr:title>Protection Induced by Simultaneous Subcutaneous and Endobronchial Vaccination with BCG/BCG and BCG/Adenovirus Expressing Antigen 85A against Mycobacterium bovis in Cattle.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/857d04956b20a9e58bfd6d4bf6d15221"><gtr:id>857d04956b20a9e58bfd6d4bf6d15221</gtr:id><gtr:otherNames>Dean GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56435410e37ec8.48864777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2764ED83-1D29-404E-A5DC-562F4FECEB80</gtr:id><gtr:title>A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5790411e8c5d561eee2f8a97bfbd48e"><gtr:id>c5790411e8c5d561eee2f8a97bfbd48e</gtr:id><gtr:otherNames>Bolinger B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13760_20_23509359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4543C32-F7DC-4F9D-8AEB-A9C606D62B71</gtr:id><gtr:title>CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38eea2cdba1a53a2340113ae7874224"><gtr:id>a38eea2cdba1a53a2340113ae7874224</gtr:id><gtr:otherNames>Lee LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>pm_13760_20_21628524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A9D7CC2-F9E8-4BBA-83C8-89405247845C</gtr:id><gtr:title>Selective presentation of MVA85A tuberculosis booster vaccine preclinical animal data.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2360a09cf36255b1c70e468e72ee2e71"><gtr:id>2360a09cf36255b1c70e468e72ee2e71</gtr:id><gtr:otherNames>Beverley P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58a6b26773ee22.25598334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>006C2587-E5A4-488B-855D-87CEE3A6CCC9</gtr:id><gtr:title>Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13760_10_18802099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42EABA79-34C6-481D-8615-4CB101BC898D</gtr:id><gtr:title>Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddeb4b513a9a22a32e1292a5aaff3615"><gtr:id>ddeb4b513a9a22a32e1292a5aaff3615</gtr:id><gtr:otherNames>Tchilian E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_13760_20_23896422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>056DD754-8ECA-4CAD-BFE7-82079C110E2B</gtr:id><gtr:title>Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a6cc6506e286a887cb628372a6d337e"><gtr:id>2a6cc6506e286a887cb628372a6d337e</gtr:id><gtr:otherNames>Davies MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13760_20_20011659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>232B55E4-9BAC-4276-B836-F1C978F04DA7</gtr:id><gtr:title>Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecfb469c69a353607a03c38a7d149e79"><gtr:id>ecfb469c69a353607a03c38a7d149e79</gtr:id><gtr:otherNames>Tchilian EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>pm_13760_10_19064635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F5622D2-D859-4358-8D04-351598C4E5C3</gtr:id><gtr:title>Harnessing local and systemic immunity for vaccines against tuberculosis.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f291f773af9424c3405959719846d950"><gtr:id>f291f773af9424c3405959719846d950</gtr:id><gtr:otherNames>Beverley PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>564b46a5a902b2.26424269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C787385-113B-4E63-9A3B-0506FB4F8E84</gtr:id><gtr:title>Simultaneous immunization against tuberculosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecfb469c69a353607a03c38a7d149e79"><gtr:id>ecfb469c69a353607a03c38a7d149e79</gtr:id><gtr:otherNames>Tchilian EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13760_20_22110657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0856E391-398F-471C-90B2-8550FDBEC7DF</gtr:id><gtr:title>Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec01007f9b88dd2817ad8edd660d0a46"><gtr:id>ec01007f9b88dd2817ad8edd660d0a46</gtr:id><gtr:otherNames>Ronan EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_13760_20_20558252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C73DB547-B8B2-4116-9D17-BEB5430833C6</gtr:id><gtr:title>Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4712fa3ac01ed7fbc4f82a7afaf1db7"><gtr:id>c4712fa3ac01ed7fbc4f82a7afaf1db7</gtr:id><gtr:otherNames>Arnold IC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>doi_55faa2aa2179d56a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AF99D41-0AF6-4D14-90D5-1DCEBF1BA620</gtr:id><gtr:title>Lessons for tuberculosis vaccines from respiratory virus infection.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f291f773af9424c3405959719846d950"><gtr:id>f291f773af9424c3405959719846d950</gtr:id><gtr:otherNames>Beverley PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>pm_13760_10_18844591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CADA54CE-679B-4AF8-A444-B2932B75E6AF</gtr:id><gtr:title>In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c57b6f510a9e6b4f58d81a550b35973"><gtr:id>9c57b6f510a9e6b4f58d81a550b35973</gtr:id><gtr:otherNames>Bayry J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_13760_10_18621704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4975A75D-D49F-4039-95AB-E6CA1CFFE055</gtr:id><gtr:title>Chemokine gene expression in lung CD8 T cells correlates with protective immunity in mice immunized intra-nasally with Adenovirus-85A.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a38eea2cdba1a53a2340113ae7874224"><gtr:id>a38eea2cdba1a53a2340113ae7874224</gtr:id><gtr:otherNames>Lee LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>pm_13760_20_20942964</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100085</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>